Study to Evaluate Restylane Vital Light Using an Injector Device

An Open, Randomized, Single-centre, Intra-individual Controlled, Explorative, Safety and Efficacy Study Comparing Restylane Vital White With no Treatment in the Face, Back of the Hands and décolletage, Using an Injector Device

The purpose of the study is to evaluate the safety and efficacy of Restylane Vital White administered with an injector device on aged skin in the face, hands and décolletage.

Study Overview

• Status: Completed
• Conditions: Aesthetics
• Intervention / Treatment: Other: No treatment; Device: Restylane Vital Light

Detailed Description

The objectives are to explore the safety and efficacy profile of Restylane Vital White administered with an injector device when one side of the face, one of the hands and one side of the décolletage is treated and the other side of the face, the other hand and the other side of the décolletage is left untreated. The face, the hands and the décolletage will be evaluated separately for both the efficacy and the safety parameters.

• Study Type: Interventional
• Enrollment (Actual): 30
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Germany
  • Hamburg, Germany, 20146
    • University of Hamburg

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years to 65 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Signed informed consent obtained
• Female subjects 40-65 years of age, inclusive.
• Visible signs of skin aging in the face, hands and décolletage (e.g. reduced skin elasticity, reduced turgor, actinic elastosis, smaller and larger wrinkles) according to the Investigators opinion.
• Subjects must be cooperative and willing to comply with the instructions and procedures.

Exclusion Criteria:

• Extensively photo damaged and aged skin according to the Investigators opinion.
• Active skin disease, inflammation or related conditions, such as infection, perioral dermatitis, seborrheic eczema and rosacea in the face, hands or décolletage.
• History of or active collagenosis (e.g. systemic lupus, erythematosis, Rheumatic arthritis, skin or systemic sclerosis)
• Previous hypersensitivity to hyaluronic acid.
• Concomitant therapy with thrombolytics or anticoagulants, or have taken inhibitors of platelet aggregation, within 2 weeks before the baseline visit.
• History of cancerous or pre-cancerous lesions in the face, hands and décolletage.
• Previous tissue augmenting therapy with non-permanent filler or treatment with botulinum toxin, aesthetic surgical therapy, laser treatment, mesotherapy, or any form of peeling in the face, hands or décolletage within 12 months prior to the baseline visit.
• Use of injectable revitalization preparations (e.g. Hyal System®, Restylane Vital) within 12 months prior to the baseline visit.
• Use of retinoic acid within 6 months prior to the baseline visit.
• Previous or concomitant treatment with chemotherapy, immunosuppressive agents or corticoids.
• History of treatment with permanent filling materials.
• Pregnancy or breast feeding woman or woman of childbearing potential not practicing adequate contraception.
• Participation in any other clinical study within 30 days prior to the baseline visit or plan to participate in another clinical study during this study period.
• Unrealistic expectation with regard to the esthetic results of the treatment.
• Planned or ongoing weight reduction program during the study.
• Known history of drug or alcohol abuse within 6 months prior to the baseline visit.
• Known hypersensitivity to one or more components of EMLA cream®.
• Any medical condition that in the opinion of the Investigator makes the subject unsuitable for inclusion (e.g. severe chronic disease, malignancy, bleeding disorder, skin diseases etc).
• Other condition preventing the subject to entering the study in the Investigator's opinion e.g. subjects anticipated to be unreliable, unable to return for the follow-up visits, not likely to avoid other prohibited treatments or procedures or incapable of understanding the information or instructions.
• Nicotine use during the study or stopped within 12 months before the baseline visit.
• Study staff or close relative of study staff (e.g. parents, children, siblings and spouse).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
OTHER: Untreated	Other: No treatment; One side of face, one hand and one side of the décolletage is left untreated as a control.
ACTIVE_COMPARATOR: Restylane Vital Light; Restylane Vital Light administered at 3 treatment sessions 4 weeks apart	Device: Restylane Vital Light; Treatment of up to 4 ml for one side of the face, one hand and one side of the décolletage dispensed by 10ul doses 0.5-1 cm apart. 3 treatment sessions 4 weeks apart.; Other Names: Restylane skinbooster

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Elasticity	To evaluate the change in elasticity from baseline for the treated and untreated side respectively.	0,4,8,12,20,28,36 weeks
GEIS subject	To evaluate esthetic change from baseline as judged by the subjects using GEIS for the treated and untreated side respectively	4,8,12,20,28,36 weeks
GEIS blinded evaluator	To evaluate esthetic change from baseline as judged by the blinded evaluator using GEIS for the treated and untreated side respectively,	12,20,28,36 weeks
Skin structure	To evaluate the change in skin structure from baseline for the treated and untreated side respectively.	0,4,8,12,20,28,36 weeks
Subject satisfaction	To evaluate subject satisfaction	0,12,20,28,36 weeks
Best skin quality by blinded live evaluation	To evaluate best skin quality of treated and untreated side judged by a blinded live evaluation	12,20,28,36 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse Events	To evaluate the safety of Restylane Vital White during the whole study by collecting Adverse Events	0-36 weeks
Subject diary	To evaluate the acute safety profile, i.e. treatment procedure reactions by direct questioning to subjects in a diary used daily for 2 weeks after each injection.	2 weeks after each treatment

Collaborators and Investigators

• Sponsor: Galderma R&D
• Investigators: Principal Investigator: Martina Kerscher, Professor, University of Hamburg, Prof. Dr. Martina Kerscher, Department Chemie, Martin-Luther-King Platz 6, 20146 Hamburg

Study record dates

Study Major Dates

• Study Start: April 1, 2009
• Primary Completion (ACTUAL): July 1, 2010
• Study Completion (ACTUAL): July 1, 2010

Study Registration Dates

• First Submitted: June 30, 2011
• First Submitted That Met QC Criteria: August 8, 2011
• First Posted (ESTIMATE): August 9, 2011

Study Record Updates

• Last Update Posted (ACTUAL): August 25, 2022
• Last Update Submitted That Met QC Criteria: August 24, 2022
• Last Verified: November 1, 2012

More Information

Terms related to this study

• Keywords: Skin rejuvenation
• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Immunologic Factors; Protective Agents; Adjuvants, Immunologic; Viscosupplements; Hyaluronic Acid
• Other Study ID Numbers: 31GR0803